M1A.2691 Drug-induced chronic gout, unspecified knee, with tophus (tophi)

Name of the Condition

• Drug-Induced Chronic Gout, Unspecified Knee, with Tophus (tophi)

Summary

Drug-induced chronic gout, unspecified knee, with tophus (tophi) is a form of arthritis affecting the knee joint, resulting from prolonged elevated uric acid levels due to medication use. It leads to recurrent joint inflammation and potential tissue damage, characterized by persistent symptoms and the presence of tophi (urate crystal deposits) in the knee area.

Causes

This condition arises from medications that interfere with uric acid metabolism or excretion, causing accumulation in the blood. Over time, urate crystals deposit in the knee joint and surrounding tissues, triggering inflammation. Common culprits include diuretics, low-dose aspirin, and certain chemotherapy agents.

Risk Factors

• Use of medications that increase uric acid levels (e.g., diuretics, low-dose aspirin)
• Prolonged exposure to urate-raising drugs
• Pre-existing hyperuricemia or gout history
• Renal impairment affecting drug clearance

Symptoms

• Recurrent episodes of intense knee pain, often with swelling and redness
• Persistent warmth and tenderness in the affected knee
• Formation of tophi (hard, painless lumps) around the knee joint
• Stiffness and limited range of motion in the knee
• Flare-ups triggered by stress, diet, or illness

Diagnosis

Diagnosis involves clinical evaluation, laboratory tests, and imaging. Blood tests may show elevated uric acid levels, while joint fluid analysis can identify urate crystals. Imaging studies like X-rays or ultrasound may reveal tophi or joint damage. The presence of tophi and a history of medication use are key diagnostic indicators.

Treatment Options

Treatment focuses on reducing uric acid levels and managing symptoms. Medications may include urate-lowering agents (e.g., allopurinol) and anti-inflammatory drugs. Intra-articular injections or surgery may be considered for tophi or severe joint damage. Lifestyle modifications, such as dietary changes, are often recommended.

Prognosis and Follow-Up

With proper management, symptoms can be controlled, and further joint damage may be prevented. Regular follow-up is essential to monitor uric acid levels and adjust treatment. Tophi may persist but can shrink with long-term therapy. Untreated cases may lead to chronic pain and disability.

Complications

• Chronic joint damage or deformity
• Persistent pain and reduced mobility
• Increased risk of kidney stones or renal impairment
• Infection of tophi if they rupture

Lifestyle & Prevention

• Avoid medications known to raise uric acid levels when possible
• Maintain a balanced diet low in purines (e.g., limit red meat, seafood)
• Stay hydrated to support uric acid excretion
• Limit alcohol consumption, especially beer and spirits
• Engage in regular, low-impact exercise to support joint health

When to Seek Professional Help

Seek medical attention if you experience severe or worsening knee pain, swelling, or redness. Prompt care is needed if tophi appear, symptoms persist despite treatment, or you develop signs of infection (e.g., fever, pus). Early intervention can prevent complications.

Tips for Medical Coders

Document the presence of tophi and the unspecified knee involvement clearly. Ensure the code M1A.2691 is used when both drug-induced chronic gout and tophus are present in the knee, with no specific laterality indicated. Verify that the medical record supports the diagnosis and any associated symptoms or complications.